Teladoc analyst commentary at Piper JaffrayTeladoc bookings up across all products and channels, says Piper Jaffray. Piper Jaffray analyst Sean Wieland says he was pleased to learn at a group breakfast with Teladoc CEO Jason Gorevik that the company's bookings are up year-over-year across all products and all channels. Further, the United deal announcement is very close and the CFO search is complete, Wieland tells investors in a research note. He views these as "two important catalysts" and remains a buyer of the stock in front of them. The analyst reiterates an Overweight rating on Teladoc with an $86 price target.Source: (thefly.com)TIGER'S TAKE: On our trading list. Good long-term growth name in the health care space.Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or comments.